• Informatie avond
  • Opleidingen
    • Master of Business Administration (MBA)
    • ‘Bedrijfskunde in de Zorg’ (pre-master)
    • ‘Marketing in de Zorg’ (post-hbo)
    • ‘Digitalisering+ in de zorg’ (masterclass)
    • Businessplan voor jouw zorgorganisatie
    • Verandermanagement (exclusieve masterclass)
    • Incompany en maatwerk
    • Partnerprogramma’s
    • Digitaal inschrijven
  • Masterclasses
    • Digitale transformatie
    • Inschrijven masterclasses
  • Blogs
    • Blogs en nieuws
    • Whitepaper
    • Boek van de maand
    • Ervaringen van deelnemers
  • Over VvAA Business School
    • Studiegids
    • Daarom VvAA Business School
    • Faculteit
    • Alumnivereniging
    • Examencommissie
    • Afstudeercommissie
    • Accreditaties
    • Bibliotheek
  • Contact
    • Contact
    • Bedrijfskundig consult
    • Informatiegesprek
    • Bel mij terug
    • Route en parkeren
    • Antwoorden op veelgestelde vragen
Dé Business School van de Nederlandse gezondheidszorg
VvAA Business SchoolVvAA Business School
  • Informatie avond
  • Opleidingen
    • Master of Business Administration (MBA)
    • ‘Bedrijfskunde in de Zorg’ (pre-master)
    • ‘Marketing in de Zorg’ (post-hbo)
    • ‘Digitalisering+ in de zorg’ (masterclass)
    • Businessplan voor jouw zorgorganisatie
    • Verandermanagement (exclusieve masterclass)
    • Incompany en maatwerk
    • Partnerprogramma’s
    • Digitaal inschrijven
  • Masterclasses
    • Digitale transformatie
    • Inschrijven masterclasses
  • Blogs
    • Blogs en nieuws
    • Whitepaper
    • Boek van de maand
    • Ervaringen van deelnemers
  • Over VvAA Business School
    • Studiegids
    • Daarom VvAA Business School
    • Faculteit
    • Alumnivereniging
    • Examencommissie
    • Afstudeercommissie
    • Accreditaties
    • Bibliotheek
  • Contact
    • Contact
    • Bedrijfskundig consult
    • Informatiegesprek
    • Bel mij terug
    • Route en parkeren
    • Antwoorden op veelgestelde vragen

Blogs en nieuws

''Ervaring delen is kennis vermenigvuldigen.''
  • Home
  • Blog
  • Blogs en nieuws
  • Revolutionizing drug research for Parkinson’s with AI’s Watson

Revolutionizing drug research for Parkinson’s with AI’s Watson

  • Posted by Ger Hofstee
  • Categories Blogs en nieuws
  • Date 22 mei 2018
  • Comments 0 comment
Whitepaper

At the age of 50 I was diagnosed with Parkinson’s disease—a chronic, neurodegenerative movement disorder for which there is no cure. Globally, roughly ten million people are affected by Parkinson’s. The mainstay symptomatic therapy, L-DOPA, is more than 50 years old. While L-DOPA is effective at reducing the symptoms of Parkinson’s for a few years, eventually it causes debilitating unwanted movements, or dyskinesia in the majority of patients taking it. After ten years of L-DOPA, up to 90 percent of patients are affected by dyskinesia—in other words, the treatment ends up being worse than the disease.

Facing these facts, the first few years after my diagnosis were bleak. Then finally one day, I had a eureka moment—could we revolutionize how new Parkinson’s treatments are being researched by using artificial intelligence?

Watson drug discovery capabilities

At IBM, I teach startups how to use Watson, IBM’s artificial intelligence platform. I know Watson’s capacity for ingesting and analyzing data, and its ability to reason and learn. One of the key challenges with finding new treatments is that getting a new drug approved for the market is a monumental task at a cost of over $2.5 billion and over a timeframe of approximately 10 years.

An easier approach is to identify drugs already approved to treat one condition, that are safe for human use, and then repurposing them for another condition. Given what I’ve seen with Watson, I thought its drug discovery capabilities could potentially accelerate finding an existing drug that could be used off-label to improve Parkinson’s patients’ quality of life.

I took the idea to my neurologist, Dr. Connie Marras. She was curious and brought in her research colleagues at the University Health Network’s Morton and Gloria Shulman Movement Disorders Centre (MDC) in Toronto, including Dr. Naomi Visanji. We formed a team—IBM Watson Health, the Ontario Brain Institute and the MDC.

Cutting through unchartered territory

First the team put together training information about dyskinesia for Watson and narrowed the scope of the study to 3,500 drugs that met some basic criteria for having the potential to be repurposed for Parkinson’s. Then within roughly 30 minutes, Watson was able to read the relevant scientific literature, absorb patterns and draw parallels between related information. The results were encouraging—within Watson’s top five percent of ranked candidate drugs, some were already known to have some potential to impact dyskinesia in pre-clinical studies. This gave us hope that Watson might find new effective drugs within its top ranked candidates.

Examining the list further, Dr. Naomi Visanji and her colleagues flagged five candidates with novel plausible antidyskinetic mechanisms of action that to her knowledge no one had considered before. According to Dr. Visanji, the first of these five drugs is undergoing lab testing and showing some exciting preliminary results that it’s working against dyskinesia. Just knowing about the other possible drugs however, wasn’t enough; they still had to be clinically tested.

Putting Watson results to the test

As a testament to our work and its potential to revolutionize how Parkinson’s patients are treated, the Canadian Institutes of Health Research (CIHR) awarded our team a grant in January 2018. This grant will cover the costs of testing the remaining top candidates in a well-established rodent model of dyskinesia and performing additional pharmacological studies that will ease the translation of any findings to future studies in primates.

Our application ranked in the top 6% of those received by the CIHR, in what is an extremely competitive environment. Our work to date could potentially impact and improve Parkinson’s patient quality of life in a matter of just a few years, easing the burden of L-DOPA-induced dyskinesia. While not a cure for Parkinson’s per se, it’s something that we hope might help improve patient’s quality of life until we have a cure.

Source: Dr. Nicky Hekster IBM.

  • Share:
author avatar
Ger Hofstee
    Oprichter en academic director van de VvAA Business School, doceert Marketing aan de EuroMBA van IAE in Aix en Provence et Marseille en is auteur van onder andere “Master in Marketing” en “World Mega Trends”.De VvAA Business School helpt jou graag om de bedrijfskundige kwaliteit van jouw (zorg)businessplan te versterken. Wij nodigen je uit gebruik te maken van de unieke mogelijkheid voor een gratis consult op jouw strategische business vraagstuk. Maak vrijblijvend een afspraak op www.vvaabusinessschool.nl/afspraak of stuur een e-mail naar ger.hofstee@vvaabusinessschool.nl.

    Previous post

    Gentest voor de zwangerschap bij huisarts
    22 mei 2018

    Next post

    Kunstmatige intelligentie van Alibaba gaat de dokter helpen!
    23 mei 2018

    You may also like

    Neemt Artificial Intelligence werk psycholoog over
    Artificial Intelligence jouw psycholoog in de toekomst?
    23 februari, 2021
    Coronavirus Colleges online
    COVID-19 – Online colleges tot 1 maart
    3 februari, 2021
    COVID-19
    COVID-19 – Online colleges tot 8 februari
    20 januari, 2021

    Leave A Reply Reactie annuleren

    Het e-mailadres wordt niet gepubliceerd.

    Download de studiegids van de VvAA Business School

     

    Laatste berichten

    Neemt Artificial Intelligence werk psycholoog over
    Artificial Intelligence jouw psycholoog in de toekomst?
    23feb2021
    Coronavirus Colleges online
    COVID-19 – Online colleges tot 1 maart
    03feb2021
    Deep Medicine - Eric Topol
    ‘Deep Medicine’
    01feb2021

    Direct naar

    • Bedrijfskunde in de zorg
    • Master of Business Administration (MBA)
    • Businessplan voor jouw zorgorganisatie
    • Verander management

    VvAA Business School

    Al sinds 2013 is de VvAA Business School dé Business School voor de Nederlandse gezondheidszorg met programma’s voor medisch specialisten en zorgprofessionals.

    Dit doen wij vanuit de unieke combinatie van relevante theorie, directe toepasbaarheid en persoonlijke ontwikkeling.

    Keurmerk crkbo

     

     

    Opleidingen

    • Master of Business Administration (MBA)
    • ‘Bedrijfskunde in de Zorg’ (pre-master)
    • Verandermanagement (masterclass)
    • ‘Marketing in de Zorg’ (post-hbo)
    • Masterclass ‘Digitalisering+ in de zorg’

    Contact

    VvAA Business School

    Slot Zeist

    Zinzendorflaan 1

    3703 CE Zeist


    +31 (0)30 227 17 63

    info@vvaabusinessschool.nl

    Direct naar

    • Over de VvAA Business School
    • Studiegids
    • Faculteit
    • Informatieavond
    • Nieuws
    • Examencommissie
    • Masterclasses
    • Contact
    • Route en parkeren
    • Nieuwsbrief

    Accreditaties

    VvAA Business School is gelieerd aan VvAA

    Algemene Voorwaarden       Privacybeleid        Cookiebeleid        Disclaimer

    Meer informatie over het Business Administration programma?

    Kom naar onze informatieavond!

    Meld je hier aan

     

    Ontvang gratis jouw Studiegids

    Studiegids VvAA Business School 2021

      Speciaal voor de zorg

      Praktijkgericht en zeer toepasbaar

      Persoonlijke begeleiding

    Meer informatie over het programma, de aanpak en wat het je oplevert.
    Direct in je mailbox!

    • Hoe gaat VvAA met uw persoonsgegevens om?

     

    ×